Among all the capabilities that cancer cells acquire during malignant progression, the ability to invade surrounding tissue and spread to distant organs is the one that most directly determines patient outcomes. Invasion and metastasis account for the vast majority of cancer-related deaths from solid tumors — not the primary tumor itself, but its dissemination. Understanding the molecular events that enable this hallmark of cancer, and developing strategies to intercept them, represents one of the most consequential areas of oncology research.
This article covers the metastatic cascade in full: from early changes in the primary tumor microenvironment through local invasion, entry into the bloodstream, systemic circulation, exit at distant organs, and colonization — highlighting the key molecular players at each stage and the therapeutic strategies being developed to disrupt them.
The Hallmarks of Cancer Framework
Activating invasion and metastasis is one of the original six hallmarks of cancer first described by Hanahan and Weinberg in their landmark 2000 paper, and it remains a central organizing concept for cancer research today. The Hallmarks of Cancer framework groups the traits that cancer cells acquire to grow and spread into a series of conceptual subsets, providing a shared vocabulary and analytical structure for research across tumor types and biological systems. The framework was expanded in 2011 with additional hallmarks and enabling characteristics, and again in 2022 with four emerging hallmarks — reflecting the ongoing evolution of our understanding of cancer biology.
Invasion and metastasis sit at the intersection of several of these hallmarks, drawing on capabilities including sustained angiogenesis, immune evasion, and metabolic reprogramming to complete the cascade from primary tumor to distant metastasis.
Early Changes in the Tumor Microenvironment
The metastatic cascade does not begin when a tumor cell enters the bloodstream. It begins much earlier, with changes in the primary tumor microenvironment (TME) that progressively remodel the tissue around the tumor to favor invasion and dissemination.
Hypoxia — the low-oxygen conditions that develop as rapidly proliferating tumors outgrow their blood supply — is a central driver of this process. Hypoxia-inducible factor (HIF) signaling is activated under low-oxygen conditions and drives the upregulation of hundreds of downstream genes involved in angiogenesis, metabolism, chronic inflammation, and extracellular matrix (ECM) remodeling. HIF activation primes the tumor for malignant behavior by creating the molecular conditions that downstream steps in the cascade require.
Simultaneously, cancer-associated fibroblasts (CAFs) — stromal cells that are recruited and activated within the TME — play a critical role in establishing the pro-invasive niche. CAFs are characterized by markers including alpha-smooth muscle actin (α-SMA), fibroblast-specific protein (FSP), and fibroblast activation protein (FAP). They are activated by inflammatory signals including IL-1, PDGF, TGF-β, and IL-6, and once activated, they remodel the ECM, increase tissue stiffness, and release factors that give tumor cells survival and motility advantages that facilitate the first steps of invasion.
Epithelial–Mesenchymal Transition: Acquiring Motility
A critical early step in tumor invasion is epithelial–mesenchymal transition (EMT) — a cellular reprogramming process in which epithelial cancer cells lose their adhesion properties and acquire the motility and invasiveness associated with a mesenchymal phenotype.
During EMT, transcription factors including SNAIL, ZEB, and TWIST repress the expression of epithelial adhesion molecules — most notably E-cadherin, which is responsible for the cell-cell junctions that maintain epithelial tissue integrity — and upregulate mesenchymal markers including N-cadherin and vimentin. The result is a profound change in cell behavior: loss of polarity, dissolution of cell-cell junctions, acquisition of a spindle-like morphology, and the ability to migrate through the surrounding tissue matrix.
EMT is induced by multiple signaling pathways that converge on these transcription factors, including TGF-β signaling, which is activated both by hypoxic primary tumor cells and by CAFs in the TME; receptor tyrosine kinase signaling downstream of EGFR and other growth factor receptors; and Wnt, Notch, and Hedgehog pathways that regulate cell fate and motility in both normal development and cancer.
ECM Remodeling and the Physical Enabling of Invasion
Concurrent with the cellular reprogramming of EMT, the physical structure of the ECM surrounding the tumor is being actively remodeled to create pathways for invasion. This remodeling is accomplished through two complementary mechanisms that work together to clear space for migrating tumor cells and create directional guidance for their movement.
Matrix metalloproteinases (MMPs) — particularly MMP-2 and MMP-9 — are secreted by both tumor cells and CAFs and degrade the protein components of the ECM, including the type IV collagen that forms the structural backbone of basement membranes. Basement membrane degradation is a prerequisite for tumor cells to breach the physical barrier that separates the epithelial compartment from the surrounding stroma and vasculature.
Simultaneously, lysyl oxidase (LOX) family enzymes — including LOXL2 — catalyze the crosslinking of collagen fibers in the ECM, increasing tissue stiffness and creating aligned collagen fiber tracks that physically guide migrating tumor cells toward sites of intravasation. The combination of ECM degradation and directed collagen remodeling creates both the physical space and the directional cues that invasive tumor cells exploit to move through the surrounding tissue.
Invadopodia, Intravasation, and the Entry into Circulation
To degrade the ECM at the invasion front with focused proteolytic activity, invasive tumor cells assemble specialized membrane protrusions called invadopodia — actin-rich structures that concentrate MMP activity precisely at the points where the tumor cell is actively breaching the ECM. Invadopodia formation is stimulated by growth factors and cytokines from tumor cells and CAFs, including VEGF and FGF, and is characterized by the presence of cortactin, TKS5, and the membrane-anchored metalloproteinase MT1-MMP (MMP14) at the invasion front.
As tumor cells degrade the ECM and migrate toward blood vessels, the vasculature itself is being remodeled by tumor-derived signals to facilitate entry. Tumor- and CAF-derived VEGF and FGF drive angiogenesis — the formation of new blood vessels to supply the growing tumor — but the tumor vasculature that results is structurally abnormal and leaky, with irregular basement membranes and gaps between endothelial cells that create sites for intravasation. The same angiogenic signals that supply nutrients to the tumor also create the vascular entry points that enable metastatic dissemination.
Immune Evasion During Circulation
Once tumor cells have entered the bloodstream as circulating tumor cells (CTCs), they face destruction by the immune system — and they have evolved sophisticated mechanisms to evade it. The immunosuppressive microenvironment that tumor cells have cultivated in the primary site travels with them into the circulation, in the form of associated immune cells that suppress cytotoxic responses against the CTCs.
Myeloid-derived suppressor cells (MDSCs) and tumor-promoting M2 macrophages — recruited by tumor- and CAF-derived factors including G-CSF, MCP-1/CCL2, IL-6, IL-1β, and CXCL12 — accompany clusters of circulating tumor cells and release immunosuppressive mediators including Arginase-1, IL-10, and PD-L1. These mediators suppress cytotoxic T cell responses, effectively shielding CTC clusters from immune destruction during their transit through the bloodstream.
M2 macrophages are characterized by markers including CD163 and CD206 and represent a distinct polarization state from the pro-inflammatory M1 macrophages that support anti-tumor immunity. The ability of tumors to recruit and maintain an M2-polarized, immunosuppressive myeloid compartment is a critical determinant of metastatic efficiency.
Extravasation: Exiting the Vasculature at Distant Sites
The exit of CTCs from the bloodstream at distant organs — extravasation — is not a random process. It occurs preferentially at specific “hot spots” where local endothelial activation and junction remodeling create conditions that favor tumor cell adhesion and transmigration.
These hot spots are established through a multi-step process. First, tumor-derived factors and extracellular vesicles travel through the circulation and are taken up by endothelial and stromal cells at select distant sites, activating the endothelium, increasing vascular permeability, and beginning to remodel the local ECM in ways that favor tumor cell attachment. E-selectin upregulation on activated endothelial cells enables the initial, transient adhesion of CTCs to the vessel wall.
Stable adhesion is then established through interactions between tumor cell integrins and endothelial adhesion molecules ICAM-1 (CD54) and VCAM-1, anchoring CTCs to the vessel wall in preparation for transmigration. Finally, tumor-derived VEGF-A activates VEGFR signaling in endothelial cells, triggering FAK/Src-mediated phosphorylation of VE-cadherin and destabilization of the VE-cadherin/β-catenin complexes at endothelial adherens junctions. This junction opening creates paracellular routes through which CTCs can exit the vasculature and enter the surrounding tissue of the distant organ.
The Premetastatic Niche: Preparing Distant Organs in Advance
One of the most conceptually striking discoveries in metastasis biology over the past two decades is the finding that primary tumors actively condition distant organs to receive metastatic cells — before any tumor cells have arrived. This premetastatic niche (PMN) is established through the secretion and systemic delivery of tumor-derived factors and extracellular vesicles that are selectively taken up by specific distant organs based on the nature of the primary tumor.
The resulting PMN is characterized by elevated levels of cytokines, growth factors, and ECM regulators including MCP-1/CCL2, CXCL12/SDF1, TGF-β, TNF, VEGF, LOX, and fibronectin. Together, these factors enhance vascular permeability, stimulate local angiogenesis, and recruit immunosuppressive cell populations — MDSCs, macrophages, and regulatory T cells (Tregs) — that ensure a permissive environment for incoming tumor cells. When CTCs arrive at a pre-conditioned PMN, they encounter a niche that has already been organized to support their survival and growth.
The organ-specificity of PMN formation — the tendency of particular tumor types to metastasize preferentially to specific organs — is partly determined by the molecular compatibility between tumor-derived vesicles and the endothelial and stromal cells of specific organs. Understanding this specificity is an active area of metastasis research with direct implications for predicting and preventing organ-specific metastasis.
Therapeutic Strategies Targeting the Metastatic Cascade
Given the central role of invasion and metastasis in cancer mortality, multiple therapeutic strategies are being developed to disrupt distinct steps of the cascade. The specificity of these interventions — targeting discrete molecular events rather than proliferation broadly — reflects the depth of mechanistic understanding that modern metastasis research has generated.
Preventing CAF Activation and TME Remodeling
Inhibition of the Hedgehog signaling pathway using small molecule inhibitors, antibody-based neutralization or inhibition of TGF-β, and small molecule inhibition of the TGF-β receptor can reduce CAF activation and dampen the pro-invasive remodeling of the TME that creates conditions for invasion. By targeting the stromal activation that amplifies tumor invasiveness, these approaches aim to prevent the establishment of the pro-invasive niche rather than targeting the tumor cells directly.
Blocking EMT
TGF-β inhibition, EGFR-targeted tyrosine kinase inhibitors, and other approaches targeting the signaling pathways that drive EMT transcription factor activity aim to prevent or reverse the mesenchymal reprogramming that gives cancer cells their invasive capacity. Limiting EMT would restrict tumor cell motility and potentially maintain tumor cells in a less invasive epithelial state.
Interfering with ECM Remodeling
LOX and LOXL2 inhibition to prevent collagen crosslinking and track formation, antibody-based blockade of fibronectin function, small molecule inhibition of collagen synthesis or crosslinking, and targeting of hyaluronan or integrin αV collectively aim to disrupt the physical ECM remodeling that enables invasion — removing the structural pathways that guide tumor cells toward intravasation sites.
Targeting Angiogenesis
Antibody-based blockade of the VEGF–VEGFR2 interaction and small molecule inhibition of FGF–FGFR signaling aim to normalize or regress the abnormal tumor vasculature that creates intravasation opportunities, while also limiting the blood supply to growing metastatic deposits. Bevacizumab, a monoclonal antibody targeting VEGF-A, is the most clinically advanced example of this approach and is approved across multiple tumor types.
Targeting Immune Evasion
Checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 counteract the immunosuppressive environment created by MDSCs and M2 macrophages at both primary and metastatic sites, potentially enabling cytotoxic T cell responses against CTCs and established metastases. The clinical success of checkpoint immunotherapy across multiple tumor types reflects the fundamental importance of immune evasion to metastatic efficiency.
Suppressing the Premetastatic Niche
LOX and LOXL2 inhibition, CXCL12–CXCR4 blockade with CXCR4 antagonists, small molecule inhibition or antibody blockade of MET, and small molecule targeting of S100A9 aim to prevent PMN establishment or dismantle existing niches before they can be colonized. Targeting the PMN represents a prophylactic approach to metastasis prevention — intervening before secondary tumors have formed rather than treating established metastatic disease.
Emerging Combination and Delivery Strategies
Beyond these individual approaches, combination strategies are being explored to address the interconnectedness of the metastatic cascade. Pairing whole-brain radiation with EGFR tyrosine kinase inhibitors to reduce lung-to-brain metastasis, and combining HER2-targeted inhibitors with capecitabine to limit breast-to-brain spread, represent examples of combination approaches targeting specific metastatic routes.
Nanoparticle-mediated drug delivery — including ultrasmall copper nanoparticles targeted to chemokine receptors such as CCR2 and loaded with chemotherapeutics including gemcitabine — offers a potential strategy for site-specific delivery to metastasis-associated immune cell populations. Early detection and targeted labeling of PMN components using antibodies or small molecules directed against LOX, S100A8/S100A9, or fibronectin may also enable interception of metastasis before secondary tumors become established.
Research Tools for Studying Invasion and Metastasis
Mechanistic investigation of invasion and metastasis depends on high-quality, validated research reagents that reliably detect the key molecular players across the cascade. The following antibodies from Cell Signaling Technology are validated for use in studying key targets in invasion, EMT, ECM remodeling, angiogenesis, immune evasion, and premetastatic niche formation:
- HIF-1α (E1V6A) Rabbit Monoclonal Antibody #48085 — WB, IHC, IF | Human, Mouse
- alpha-Smooth Muscle Actin (D4K9N) Rabbit Monoclonal Antibody #19245 — WB, IP, IHC, IF | Human, Mouse, Rat, Hamster, Monkey
- FAP (F1A4G) Rabbit Monoclonal Antibody #52818 — WB, IP, IHC, F | Human
- Snail (C15D3) Rabbit Monoclonal Antibody #3879 — WB, IP | Human, Mouse, Rat, Monkey
- Slug (C19G7) Rabbit Monoclonal Antibody #9585 — WB, IP, IF, F | Human, Mouse
- ZEB1 (E2G6Y) Rabbit Monoclonal Antibody #70512 — WB, IP, IHC, IF, F | Human, Mouse, Rat
- TWIST1 (E5G9Y) Rabbit Monoclonal Antibody #90445 — WB, IF | Human, Mouse
- N-Cadherin (D4R1H) Rabbit Monoclonal Antibody #13116 — WB, IP, IHC, IF | Human, Mouse
- Vimentin (D21H3) Rabbit Monoclonal Antibody #5741 — WB, IHC, IF, F | Human, Mouse, Rat, Hamster, Monkey
- MMP-2 (D4M2N) Rabbit Monoclonal Antibody #40994 — WB, IP, IHC, IF | Human
- MMP-9 (D6O3H) Rabbit Monoclonal Antibody #13667 — WB, IHC, F | Human
- COL1A1 (E8F4L) Rabbit Monoclonal Antibody #72026 — WB, IHC, IF | Human, Mouse, Rat, Monkey
- LOX (D8F2K) Rabbit Monoclonal Antibody #58135 — WB | Human, Mouse
- LOXL2 (E3P7Y) Rabbit Monoclonal Antibody #99680 — WB, IHC | Human
- Basic FGF (E5Y6M) Rabbit Monoclonal Antibody #46879 — WB, IHC, IF | Human, Mouse
- VEGF-A (E9X8Q) Rabbit Monoclonal Antibody #50661 — WB, IP | Human
- VEGF Receptor 2 (D5B1) Rabbit Monoclonal Antibody #9698 — WB, IP, IHC, IF, F | Human, Mouse, Rat
- Arginase-1 (D4E3M) Rabbit Monoclonal Antibody #93668 — WB, IHC, IF, F | Human, Mouse, Rat
- PD-L1 (E1L3N) Rabbit Monoclonal Antibody #13684 — WB, IP, IHC, F | Human
- CD54/ICAM-1 (E3Q9N) Rabbit Monoclonal Antibody #67836 — WB, IHC | Human, Monkey
- VCAM-1 (D2T4N) Rabbit Monoclonal Antibody #32653 — WB, IHC | Mouse
- VE-Cadherin (F4K3Y) Rabbit Monoclonal Antibody #60787 — WB, IP, IHC, IF | Mouse
- SDF1/CXCL12 (D8G6H) Rabbit Monoclonal Antibody #97958 — IHC | Human
- Fibronectin/FN1 (E5H6X) Rabbit Monoclonal Antibody #26836 — WB, IP, IHC, IF | Human
- TGF-β (56E4) Rabbit Monoclonal Antibody #3709 — WB | Human
As spatial profiling, single-cell sequencing, and high-resolution imaging continue to sharpen our view of the metastatic cascade, they will reveal additional druggable vulnerabilities in both tumor cells and their niches — advancing the field from describing invasion and metastasis toward actively and specifically intercepting them.